Join our daily newsletter At The Bell to receive exclusive market insights
- Anteris Technologies (AVR) reports eight patients showed clinically significant improvements under the first-in-human DurAVR Transcatheter Heart Valve (THV) study
- There was an 81 per cent decrease in the mean pressure gradient and an average 300 per cent increase in effective orifice area
- The study is being performed at the Tbilisi Heart and Vascular Clinic in Georgia with all 13 patients continuing to show marked improvements from their pretreatment levels
- This data comes from 30-day follow-up results with further data to be released at the 12-month mark
- Shares in Anteris are down a slight 0.89 per cent and were trading at $27.80 at 11:47 am AEST
Anteris Technologies (AVR) has reported eight patients showed clinically significant improvements under the first-in-human DurAVR Transcatheter Heart Valve (THV) study.
There was an 81 per cent decrease in the mean pressure gradient with patients ranging from -89 to -74 per cent and an average 300 per cent increase in effective orifice area ranging from 217 to 582 per cent.
The study is being performed at the Tbilisi Heart and Vascular Clinic in Georgia with all 13 patients continuing to show marked improvements from their pretreatment levels.
This data comes from 30-day follow-up results with further data to be released at the 12-month mark.
The THV is designed to be a functional cure for severe aortic stenosis which is a condition where the heart’s aortic valve narrows, reducing blood flow to the body and forcing the heart to work faster.
“The data so far is extremely encouraging and fulfilling the hypothesis that DurAVR works
better and lasts longer. As we move into the second half, we will continue enrolling patients into our studies (Europe and FDA EFS) and gathering data for presentation at the major conferences as well as regulatory filings throughout the rest of the year,” CEO Wayne Paterson said.
“We will continue generating non-patient data as well with leading research institutions that demonstrate DurAVR’s superior flow characteristics compared with competitor valves as well as other relevant data.”
Shares in Anteris were down a slight 0.89 per cent and were trading at $27.80 at 11:47 am AEST.
